| Market Cap | 57.85M | P/E | - | EPS this Y | -11.20% | Ern Qtrly Grth | - |
| Income | -61.23M | Forward P/E | -1.39 | EPS next Y | -5.90% | 50D Avg Chg | 3.00% |
| Sales | 7.16M | PEG | -0.05 | EPS past 5Y | - | 200D Avg Chg | -11.00% |
| Dividend | N/A | Price/Book | 0.82 | EPS next 5Y | 17.00% | 52W High Chg | -50.00% |
| Recommedations | 2.50 | Quick Ratio | 3.33 | Shares Outstanding | 5.48M | 52W Low Chg | 44.00% |
| Insider Own | 33.10% | ROA | -33.87% | Shares Float | 3.63M | Beta | 0.61 |
| Inst Own | 13.15% | ROE | -98.95% | Shares Shorted/Prior | 42.60K/19.61K | Price | 1.11 |
| Gross Margin | 70.46% | Profit Margin | - | Avg. Volume | 104,867 | Target Price | 36.00 |
| Oper. Margin | -175.22% | Earnings Date | May 2 | Volume | 75,741 | Change | 1.83% |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases in the United States. It develops ABI-5366 and ABI-1179, which is in Phase 1a/1b clinical trial targeting recurrent genital herpes; and ABI-6250, an oral hepatitis delta virus entry inhibitor that is in Phase 1a clinical studies. The company also offers ABI-4334, a next-generation capsid assembly modulator which is in Phase 1b clinical trials, for the treatment of hepatitis B virus. In addition, it provides an oral non-nucleoside polymerase inhibitor indicated for transplant-associated herpesviruses; and small molecule interferon-a receptor to treat hepatitis B and delta virus. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. It also has license agreement with Indiana University Research and Technology Corporation to develop and commercialize products for its HBV programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
| HC Wainwright & Co. | Neutral | Apr 1, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Schornstein Alexander | 10% Owner 10% Owner | Jan 17 | Buy | 0.79 | 645,080 | 509,613 | 8,209,372 | 01/19/24 |
| Okazaki Jason A | CEO and President CEO and President | Aug 02 | Sell | 1.0879 | 11,827 | 12,867 | 164,786 | 08/03/23 |
| McHutchison John G | Director Director | May 22 | Sell | 1.04 | 25,972 | 27,011 | 169,160 | 05/24/23 |
| Bjorkquist Jeanette M | Principal Accounting.. Principal Accounting Officer | May 22 | Sell | 1.04 | 274 | 285 | 27,532 | 05/24/23 |
| Delaney William E IV | Chief Scientific Off.. Chief Scientific Officer | May 22 | Sell | 1.04 | 6,561 | 6,823 | 116,437 | 05/24/23 |
| Okazaki Jason A | CEO and President CEO and President | May 22 | Sell | 1.04 | 6,561 | 6,823 | 126,613 | 05/24/23 |
| McHutchison John G | Director Director | Mar 30 | Sell | 0.8232 | 14,883 | 12,252 | 177,632 | 03/31/23 |
| Bjorkquist Jeanette M | Principal Accounting.. Principal Accounting Officer | Feb 16 | Sell | 0.82 | 774 | 635 | 23,806 | 03/31/23 |
| Delaney William E IV | Chief Scientific Off.. Chief Scientific Officer | Mar 29 | Sell | 0.8232 | 3,421 | 2,816 | 85,498 | 03/31/23 |
| McHutchison John G | Chief Executive Offi.. Chief Executive Officer | Aug 08 | Sell | 2.1277 | 12,314 | 26,200 | 192,515 | 08/10/22 |
| Samar Michael P. | Chief Financial Offi.. Chief Financial Officer | Jul 25 | Sell | 2.2174 | 2,020 | 4,479 | 77,228 | 07/26/22 |
| Delaney William E IV | Chief Scientific Off.. Chief Scientific Officer | May 31 | Sell | 1.9224 | 4,164 | 8,005 | 76,419 | 06/02/22 |
| Samar Michael P. | Chief Financial Offi.. Chief Financial Officer | Mar 29 | Sell | 2.17 | 2,285 | 4,958 | 76,748 | 03/31/22 |
| Stamm Luisa M | Chief Medical Office.. Chief Medical Officer | Mar 29 | Sell | 2.17 | 1,038 | 2,252 | 40,315 | 03/31/22 |
| Delaney William E IV | Chief Scientific Off.. Chief Scientific Officer | Mar 29 | Sell | 2.17 | 1,038 | 2,252 | 78,083 | 03/31/22 |
| Okazaki Jason A | Chief Operating Offi.. Chief Operating Officer | Mar 29 | Sell | 2.17 | 1,269 | 2,754 | 94,614 | 03/31/22 |
| McHutchison John G | CEO and President CEO and President | Mar 29 | Sell | 2.17 | 4,614 | 10,012 | 204,829 | 03/31/22 |
| Okazaki Jason A | Chief Operating Offi.. Chief Operating Officer | Mar 28 | Sell | 2.2445 | 4,617 | 10,363 | 64,633 | 03/29/22 |